AT Polaris Medicine
Semaglutide
Semaglutide
Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Initially approved for diabetes treatment, semaglutide has also been indicated for weight management in individuals with obesity, leading to significant weight loss in clinical trials. Its potential benefits extend beyond glycemic control, with studies suggesting improvem
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Initially approved for diabetes treatment, semaglutide has also been indicated for weight management in individuals with obesity, leading to significant weight loss in clinical trials. Its potential benefits extend beyond glycemic control, with studies suggesting improvements in cardiovascular health as well. As a once-weekly injection or a daily oral formulation, semaglutide offers flexibility for patients looking to enhance their diabetes management or achieve weight loss goals.
Tirzepetide
Semaglutide
Semaglutide
Tirzepetide is a novel medication designed for the treatment of type 2 diabetes, functioning as a dual agonist for the GLP-1 and GIP (gastric inhibitory polypeptide) receptors. This innovative approach not only helps improve glycemic control but also promotes weight loss by enhancing insulin secretion and reducing appetite. Administered
Tirzepetide is a novel medication designed for the treatment of type 2 diabetes, functioning as a dual agonist for the GLP-1 and GIP (gastric inhibitory polypeptide) receptors. This innovative approach not only helps improve glycemic control but also promotes weight loss by enhancing insulin secretion and reducing appetite. Administered via subcutaneous injection, tirzepetide represents a promising advancement in the management of metabolic disorders, with the potential for beneficial effects on cardiovascular health as well.